Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment

Executive Summary

REMS assessment schedule for the long-acting/extended release opioid products reflects the large number of drugs, prescribers and patients involved in the risk management program and the time needed to put all its components in place.


Related Content

Endo's Belbuca Is First Buccal Film In Extended-Release Opioid Class
Opioid Post-marketing Studies: Can Sponsors Work Well Together Again?
Shared REMS Systems Show Challenges Of Standardization – Could PDUFA V Help?
Opioid Training Syllabus Increases Emphasis On Patient Monitoring In Final REMS Blueprint
Mandatory Training For Opioid Prescribers Remains Stuck On Drawing Board
OxyContin Abuse-Deterrent Formulation Has Addicts Switching To Heroin
One-Page MedGuide For Long-acting Opioids Sets Stage For Retooling MedGuide Format
Long-Acting Opioid REMS Tally: FDA Lists 12 Brand, 23 Generic
REMS Clock Ticking: Sponsors Grapple With Assessment Time Constraints
REMS Assessments For Opioids Will Require Data From Across Health System





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts